PREVALENCE AND INCIDENCE OF TYPE 2 DIABETES MELLITUS- AN ANALYSIS BASED ON 5.4 MILLION PATIENTS

Author(s)

Wilke T1, Groth A2, Mueller S2, Ahrendt P2, Schwartz D2, Linder R3, Ahrens S3, Verheyen F31Hochschule Wismar, Wismar, Germany, 2IPAM Wismar, Wismar, Germany, 3Scientific Institute of Techniker Krankenkasse for Benefit and Efficiency in Health Care, Hamburg, Germany

OBJECTIVES: The aims of this contribution are to update and more precisely quantify the existing data concerning age/gender-specific prevalence and incidence of type 2 diabetes mellitus (T2DM) in an European setting (Germany). METHODS: To fulfill the aims of the study, a population-based analysis of the claims data collected by a statutory health insurance fund, and concerning its 5.4 million members, was done. A patient was classified as T2DM prevalent if he/she had received at least one inpatient and/or two outpatient diagnoses of T2DM (ICD10 code E11) in two different quarters between 01/01/2006 and 12/31/2008. A patient was considered to have had new onset T2DM in 2008 under one of three conditions; firstly, he/she had not received a diagnosis of T2DM in 2006 and 2007; secondly, had not received oral anti-diabetics in 2006/2007; and thirdly, had received either one inpatient or two outpatient T2DM diagnosis in 2008. RESULTS: In our sample, a total of 254,523 patients had T2DM. The prevalence of T2DM was 4.69 % (women: 3.26%; men: 6.03%). The average age of these T2DM patients was 64.8 years, and 66.4% were male. The incidence of T2DM in our sample was 4.889 cases per 1,000 person-years in men and 2.863 cases in 1,000 person-years in women. T2DM prevalence/incidence strongly depended on gender and age. Whereas the T2DM prevalence in both men and women was below 0.9% in all age groups <40 years, it increased up to 25.17% (men)/24.34% (women) in the second-highest age group, 85-90 years. CONCLUSIONS: A comparison of the distribution of AF prevalence/incidence in our population with that in already published studies shows that our figures are comparatively high. Obviously, in a large industrial nation such as Germany, care provision structures are going to be challenged by the requirement to treat more T2DM patients in the future.

Conference/Value in Health Info

2012-06, ISPOR 2012, Washington, D.C., USA

Value in Health, Vol. 15, No. 4 (June 2012)

Code

PDB24

Topic

Epidemiology & Public Health

Disease

Diabetes/Endocrine/Metabolic Disorders

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×